Sanofi targeted in vaccine pricing suit; Seattle Genetics lays groundwork for wider Adcetris approval;

 @FiercePharma: Packaging veteran urges including patient in drug pedigree chain. Story | Follow@FiercePharma

> Glenmark Pharma seeks arbitration to get Napo Pharmaceuticals to keep to a collaboration agreement between the two companies. Article

> New York's governor signs a bill that takes aim at mail-order pharmacies. Report

> Sanofi ($SNY) is named in suit over meningococcal vaccine pricing practices. Item

> Biopharma companies shutter 38 plants in 2011, down from 65 in 2010. Report

> Seattle Genetics' lymphoma drug Adcetris could gain approval for use in a larger market after a small study showed its benefits when used with other therapies. Item

Biotech News

 @FierceBiotech: In another rare disease push, GSK is teaming with University of Dundee researchers to find Huntingdon's treatment. Report | Follow @FierceBiotech

 @JohnCFierce: Strong arguments from Harvard's Carpenter on making FDA independent. Not gonna happen, but it's an intelligent piece. Article | Follow @JohnCFierce

> Drug companies steer toward automakers for advice. Story 

> Venture survey forecasts tough life sciences investment scene for 2012. Item 

Drug Delivery News

> Immunomedics promotes 2 cancer treatments to later-stage trials. News

> India university creates low-cost insulin pump: commercial partners wanted. Report

> Nanoparticles carting steroids to retina delay macular degeneration. Item

> Silk may be basis for smoothest microneedle system yet. Article

Biomarkers News

> Biomarkers provide route to personalized medicine. Piece

> BNP may serve as prognostic biomarker in valve disease. News

> Next-gen sequencing pinpoints breast cancer biomarkers. Story

> Diabetes collaboration to identify biomarkers. Item

Medical Devices News

> Infrascan gets FDA's OK for hematoma detector. News

> Ventana, ACD ink co-promotion deal. Item

> Final Synthes exec sentenced in Norian case. Report

> Baxter enters agreement to buy Synovis for $325M. Article

And Finally... The FDA is cracking down on the marketing practices of 1-800-GET-THIN. Article

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.